{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:16:31Z","timestamp":1789600591557,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.semarthrit.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T10:20:09Z","timestamp":1552126809000},"page":"222-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-3579","authenticated-orcid":false,"given":"Seoyoung C.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajinkya","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0299-7273","authenticated-orcid":false,"given":"Rishi J.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Sarsour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2019.03.002_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2019.03.002_bib0002","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.03.002_bib0003","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.03.002_bib0004","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.03.002_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2014.06.012","article-title":"The comparative safety of TNF inhibitors in rheumatoid arthritis - a meta-analysis update of 44 randomized controlled trials","author":"Michaud","year":"2014","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2019.03.002_bib0006","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","volume":"32a","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semarthrit.2019.03.002_bib0007","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.03.002_bib0008","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.03.002_bib0009","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.semarthrit.2019.03.002_bib0010","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstrom","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"12","key":"10.1016\/j.semarthrit.2019.03.002_bib0011","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1136\/annrheumdis-2017-211623","article-title":"Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.03.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/art.39689","article-title":"Biologic disease-modifying antirheumatic drugs and risk of high-grade cervical dysplasia and cervical cancer in rheumatoid arthritis: a cohort study","author":"Kim","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2019.03.002_bib0013","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1136\/annrheumdis-2015-208263","article-title":"Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden","volume":"75","author":"Wadstrom","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2019.03.002_bib0014","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.03.002_bib0015","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy","volume":"42","author":"Aaltonen","year":"2015","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.03.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000213","article-title":"Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab","volume":"2","author":"Rubbert-Roth","year":"2016","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.semarthrit.2019.03.002_bib0017","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2019.03.002_bib0018","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.03.002_bib0019","series-title":"Pharmacoepidemiology","first-page":"209","article-title":"US government claims databses","author":"Hennessy","year":"2012"},{"issue":"12","key":"10.1016\/j.semarthrit.2019.03.002_bib0020","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.cgh.2007.07.012","article-title":"The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States","volume":"5","author":"Kappelman","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2019.03.002_bib0021","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.amjcard.2015.11.035","article-title":"A US claims-based analysis of real-world lipid-lowering treatment patterns in patients with high cardiovascular disease risk or a previous coronary event","volume":"117","author":"Quek","year":"2016","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.semarthrit.2019.03.002_bib0022","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3899\/jrheum.131464","article-title":"Tumor necrosis factor-alpha inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study","volume":"41","author":"Desai","year":"2014","journal-title":"J Rheumatol."},{"issue":"1","key":"10.1016\/j.semarthrit.2019.03.002_bib0023","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/ar3260","article-title":"Validation of rheumatoid arthritis diagnoses in health care utilization data","volume":"13","author":"Kim","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2019.03.002_bib0024","first-page":"561","article-title":"Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data","volume":"18","author":"Setoguchi","year":"2007","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.semarthrit.2019.03.002_bib0025","series-title":"Cancer facts & figures 2013","year":"2013"},{"issue":"11","key":"10.1016\/j.semarthrit.2019.03.002_bib0026","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/pds.3520","article-title":"Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer","volume":"22","author":"Kim","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.semarthrit.2019.03.002_bib0027","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.22056","article-title":"Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis","volume":"54","author":"Setoguchi","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.03.002_bib0028","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2019.03.002_bib0029","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/pds.2315","article-title":"A systematic review of validated methods for identifying lymphoma using administrative data","volume":"21","author":"Herman","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.semarthrit.2019.03.002_bib0030","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.semarthrit.2019.03.002_bib0031","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar2482","article-title":"Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study","volume":"10","author":"Ting","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"8 Pt 2","key":"10.1016\/j.semarthrit.2019.03.002_bib0032","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00064","article-title":"Estimating causal effects from large data sets using propensity scores","volume":"127","author":"Rubin","year":"1997","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2019.03.002_bib0033","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/pds.3263","article-title":"One-to-many propensity score matching in cohort studies","volume":"21","author":"Rassen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.03.002_bib0034","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"10","key":"10.1016\/j.semarthrit.2019.03.002_bib0035","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.03.002_bib0036","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0001-4575(01)00108-7","article-title":"Matched-pair cohort methods in traffic crash research","volume":"35","author":"Cummings","year":"2003","journal-title":"Accid Anal Prev"},{"issue":"8210","key":"10.1016\/j.semarthrit.2019.03.002_bib0037","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(81)90116-1","article-title":"Vasectomy and non-fatal myocardial infarction","volume":"1","author":"Walker","year":"1981","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.semarthrit.2019.03.002_bib0038","doi-asserted-by":"crossref","first-page":"809","DOI":"10.18553\/jmcp.2017.23.8.809","article-title":"Temporal trends in use of biologic DMARDs for rheumatoid arthritis in the United States: a cohort study of publicly and privately insured patients","volume":"23","author":"Desai","year":"2017","journal-title":"J Managed Care Specialty Pharmacy"},{"issue":"5","key":"10.1016\/j.semarthrit.2019.03.002_bib0039","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/annrheumdis-2017-212407","article-title":"Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis","volume":"77","author":"Fraenkel","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2019.03.002_bib0040","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.semarthrit.2019.03.002_bib0041","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218305894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218305894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:59:11Z","timestamp":1758733151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017218305894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0049017218305894"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.03.002","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}